Bioprocessing and biotechnology

From vaccines and pharmaceuticals, to biofuels, food and household goods, developments in bioprocessing and biotechnology have the potential to significantly influence the future of manufacturing, medicine and energy. Significant challenges remain in many areas, such as complex regulatory issues and the ever-present need to improve productivity and consistency, whilst reducing costs, resulting in the generation of highly valuable and eminently protectable innovation for our clients.

Progress in bioprocessing within the pharmaceutical sector is motivated by a growing demand for novel therapeutics, including biopharmaceutical medicines and vaccines, and the rapid emergence of disruptive cell and gene therapy treatments.

In the energy sector, research and development is spurred by public desire and government support for more efficient, cleaner systems that enable a shift away from traditional petrochemicals.

And in food and nutrition, growing demands for meat replacements, increased shelf life, enhanced quality and health-promoting products are all influencing a range of technological developments.

These, and other areas of bioprocessing and biotechnology, are underpinned by a plethora of technologies, from vector design to process control, fermenter engineering to product recovery. HGF has been at the cutting-edge of developments in bioprocessing and biotechnology for many years, with a specialist team combining comprehensive scientific knowledge and commercial understanding to develop and implement legally and commercially astute IP strategies. Working with a wide range of clients, from global pharmaceutical and biotech companies, to SMEs and universities, the team supports innovation across all sectors.

Latest updates

Event - 30th January 2024

CAR-TCR Summit, Europe 2024

HGF are proud Event Partners of CAR-TCR Europe, which is due to go ahead from 27th – 29th February at ExCeL, Royal Victoria Dock in London. This is the European hub …

Event details

First CRISPR therapy approved for use in the UK

In an unprecedented move, the MHRA has approved a CRISPR gene editing therapy ‘Casgevy’  for the treatment of sickle cell disease and beta-thalassaemia in patients with recurrent vaso-occlusive crises. The Casgevy …

Read article
Event - 23rd-24th April 2024

Microbiome & Probiotic R&D & Business Collaboration Forum: Europe

The Microbiome & Probiotic R&D & Business Collaboration Forum is set to take place in Rotterdam on the 23rd-24th April 2024. This world-renowned event will see three conferences and eight …

Event details

IAM Patent 1000 2023

IAM Patent 1000 the world’s leading patent professionals 2023 guide has now been published and we are delighted to have 31 attorneys recognised as world-class individuals in the guide. The …

Read article

What is EUDAMED and how will it affect your IP strategy?

The “European database on medical devices”, or “EUDAMED”, is the EU’s IT system created by the new Medical Devices Regulation (MDR) and In Vitro Diagnostics Medical Devices Regulation (IVDR). When …

Read article
Event - 8th-9th February 2023

5th Annual Microbiome & Probiotic Conference 2023

The 5th Annual MarketsandMarkets Next Gen Microbiome and Probiotics Conference will take place in San Diego on the 8th-9th of February. This conference will enable you to learn about microbial …

Event details
Event - 29th November 2022

LSPN Europe 2022

HGF is a silver sponsor of LSPN Europe 2022 on 29th November in London. This event will explore some of the biggest challenges facing the Life Sciences Patent Community right now …

Event details

Food technology companies and investors - the value of IP landscape analysis

Case study – alt fat innovation Many companies and investors are aware of the importance of identifying and protecting their innovations, and in particular of the importance of obtaining patents …

Read article

Let's talk

If you would like to discuss how HGF could help you, contact one of our bioprocessing & biotechnology specialists.